FDA revises guidance on IRB review of expanded access submissions to reflect end of public health emergency
Regulatory NewsJoanne S. Eglovitch
BiologicsBiotechnologyNorth AmericaPharmaceuticalsRegulatory NewsJoanne S. EglovitchBiologicsBiotechnologyNorth AmericaPharmaceuticals